New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.
Hemolytic uremic syndrome (HUS) is a disease characterized by microangiopathic hemolytic anemia, consumptive thrombocytopenia, and renal impairment. Often HUS is triggered by Shiga-like toxin- producing ESCHERICHIA COLI. Less common is atypical HUS (aHUS), which is caused by defective complement control. aHUS is associated with mutations in genes encoding complement regulatory proteins in ~50% of patients with this syndrome. Furthermore, autoantibodies that inactivate to factor H have also been linked to the disease. Initial triggers include infections, use of endothelial-affecting drugs, malignancies, transplantation, and pregnancy. Advances in our understanding of the pathogenesis of atypical HUS suggest that complement inhibition may be used as treatment for the disease. We discuss the potential benefit of the complement inhibitor eculizumab for the treatment of aHUS.
Köse
Ozlem
O
Department of Nephrology, University Hospital of Essen, University Duisburg-Essen, Essen, Germany.
Zimmerhackl
Lothar-Bernd
LB
Jungraithmayr
Therese
T
Mache
Christoph
C
Nürnberger
Jens
J
D000328:Adult; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D003180:Complement C3b Inactivator Proteins / Q000235:genetics; D003182:Complement C5 / Q000276:immunology*; D017242:Complement Factor H / Q000235:genetics; D003170:Complement Pathway, Alternative / Q000187:drug effects / Q000276:immunology; D005260:Female; D017353:Gene Deletion; D006463:Hemolytic-Uremic Syndrome / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D006801:Humans; D009154:Mutation; D011110:Polymorphism, Genetic; D016896:Treatment Outcome; D055815:Young Adult
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C517621:CFHR1 protein, human; D003180:Complement C3b Inactivator Proteins; D003182:Complement C5; D017242:Complement Factor H; C481642:eculizumab